search
Back to results

Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials (the ACT2 Project)

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Peer-driven intervention
Time-matched health education
Sponsored by
New York University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV Infections

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria for Initial Seeds:

  • HIV infected
  • Seen at the Betances Health Center or AIDS Service Center at least once in the last 6 months prior to study entry
  • Of African-American or Latino descent
  • Willing to recruit HIV infected peers
  • Able to conduct research activities (e.g., speaking and writing when necessary) in English

Inclusion Criteria for Peers:

  • Documented recruitment for study participation
  • HIV infected
  • Willing to recruit HIV infected peers
  • Able to conduct research activities (e.g., speaking and writing when necessary) in English

Exclusion Criteria:

  • Currently enrolled in an HIV/AIDS clinical trial
  • Currently psychotic based on standard assessment (e.g., MINI, Lecrubier et al., 1997)
  • Any condition that, in the opinion of the investigator, would interfere with participation in the study

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    1

    2

    Arm Description

    Control

    Outcomes

    Primary Outcome Measures

    Participation in screening for AIDS clinical trials to the point of determining eligibility, coded as yes/no.
    During interventions, participants in both arms receive contact information for local AIDS clinical trials units. Two sources of data are used to determine whether screening occurred. First, for participants screened at Beth Israel Medical Center, the study's main collaborating site, the screener notes the screening event in a participant status file. Second, during follow-up interviews at 16 and 52 weeks post-baseline, participants' screening experiences at other units are assessed. This self-reported screening is confirmed with the clinical trials units (all screening reports are verified).

    Secondary Outcome Measures

    Enrollment into an AIDS clinical trial or HIV/AIDS biomedical research study
    Two sources of data are used to determine whether enrollment occurred. First, for participants screened at Beth Israel Medical Center, the study's main collaborating site, study staff confirms participation in the trial with participants and trials units and log this in a participant status file. Second, during follow-up interviews at 16 and 52 weeks post-baseline, enrollment in studies and trials is assessed. This self-reported enrollment is confirmed with the clinical trials units (all enrollment reports are verified).

    Full Information

    First Posted
    January 2, 2008
    Last Updated
    October 31, 2022
    Sponsor
    New York University
    Collaborators
    National Institute of Allergy and Infectious Diseases (NIAID), Beth Israel Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00593983
    Brief Title
    Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials (the ACT2 Project)
    Official Title
    Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2012
    Overall Recruitment Status
    Completed
    Study Start Date
    May 2007 (undefined)
    Primary Completion Date
    April 2011 (Actual)
    Study Completion Date
    April 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    New York University
    Collaborators
    National Institute of Allergy and Infectious Diseases (NIAID), Beth Israel Medical Center

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    African Americans and Latinos are increasingly affected by HIV/AIDS in the United States. Despite the increase in the number of infections in minority populations, these individuals are not adequately represented in AIDS clinical trials (ACTs). The purpose of this study is to identify effective intervention strategies to increase the number of HIV infected racial/ethnic minorities and women who are screened for and enrolled into ACTs.
    Detailed Description
    According to a 2001 report by the U.S. Census Bureau, African Americans and Latinos make up 65% of all AIDS cases reported in the United States, yet they make up only 25% of the population in the United States. In addition, the number of women living with HIV/AIDS, many of whom are minorities, is rapidly increasing. ACTs are research studies designed to evaluate new therapies to fight HIV infection and prevent and treat opportunistic infections and cancers associated with AIDS. Preliminary research suggests that intensive intervention efforts are needed to improve rates of screening and to enroll more racial/ethnic minorities and women in ACTs. The purpose of this study is to identify effective intervention strategies to increase the low number of HIV infected racial/ethnic minorities and women who are screened for and enrolled into ACTs. Each participant will be enrolled in the study for 12 months. Participants will be randomly assigned to either the intervention or control arm. Initial "seed" participants in the intervention arm will complete a peer-driven intervention consisting of four structured intervention sessions lasting 6 hours in total (occurring every week for 4 weeks), three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening. Participants in the control arm will complete a time-matched health education intervention lasting 6 hours. Participants in the control arm will also receive the community standard of care and be referred to their local ACT unit. Peer participants will be recruited by either a seed or through general recruitment; those recruited by an initial seed will participate in the same arm as the see d who recruited them. Study visits will occur throughout the study. Participants in the intervention arm will complete an interview at Week 30. At Weeks 8, 16 and 52, all participants will complete social impact assessments. At Weeks 16 and 52, all participants will complete follow-up visits.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    HIV Infections

    7. Study Design

    Primary Purpose
    Health Services Research
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    540 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Arm Title
    2
    Arm Type
    Placebo Comparator
    Arm Description
    Control
    Intervention Type
    Behavioral
    Intervention Name(s)
    Peer-driven intervention
    Intervention Description
    Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
    Intervention Type
    Behavioral
    Intervention Name(s)
    Time-matched health education
    Intervention Description
    Health education and standard of care treatment
    Primary Outcome Measure Information:
    Title
    Participation in screening for AIDS clinical trials to the point of determining eligibility, coded as yes/no.
    Description
    During interventions, participants in both arms receive contact information for local AIDS clinical trials units. Two sources of data are used to determine whether screening occurred. First, for participants screened at Beth Israel Medical Center, the study's main collaborating site, the screener notes the screening event in a participant status file. Second, during follow-up interviews at 16 and 52 weeks post-baseline, participants' screening experiences at other units are assessed. This self-reported screening is confirmed with the clinical trials units (all screening reports are verified).
    Time Frame
    within the participant's 52 week follow up period
    Secondary Outcome Measure Information:
    Title
    Enrollment into an AIDS clinical trial or HIV/AIDS biomedical research study
    Description
    Two sources of data are used to determine whether enrollment occurred. First, for participants screened at Beth Israel Medical Center, the study's main collaborating site, study staff confirms participation in the trial with participants and trials units and log this in a participant status file. Second, during follow-up interviews at 16 and 52 weeks post-baseline, enrollment in studies and trials is assessed. This self-reported enrollment is confirmed with the clinical trials units (all enrollment reports are verified).
    Time Frame
    within the participant's 52 week follow-up period

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria for Initial Seeds: HIV infected Seen at the Betances Health Center or AIDS Service Center at least once in the last 6 months prior to study entry Of African-American or Latino descent Willing to recruit HIV infected peers Able to conduct research activities (e.g., speaking and writing when necessary) in English Inclusion Criteria for Peers: Documented recruitment for study participation HIV infected Willing to recruit HIV infected peers Able to conduct research activities (e.g., speaking and writing when necessary) in English Exclusion Criteria: Currently enrolled in an HIV/AIDS clinical trial Currently psychotic based on standard assessment (e.g., MINI, Lecrubier et al., 1997) Any condition that, in the opinion of the investigator, would interfere with participation in the study
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Marya Gwadz, PhD
    Organizational Affiliation
    New York University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials (the ACT2 Project)

    We'll reach out to this number within 24 hrs